Detecting Atrial Fibrillation Using Smartwatches by Agnieszka Kulczycka-Rowicka, Julianna Podolec, Silvia Ciraolo, Joanna Wojda, Adam Sobiński, Zuzanna Kościuszko, Katarzyna Kurza, Matylda Czerwonka, Katarzyna Lesiczka-Fedoryj, Anna Walczak

Subjects: Get full text

Commentary: Oil and gas development exposure and atrial fibrillation exacerbation: a retrospective study of atrial fibrillation exacerbation using Colorado's all payer claims dataset by Judy Wendt Hess

Subjects: “…atrial fibrillation…”
Get full text

A machine learning-based model for predicting paroxysmal and persistent atrial fibrillation based on EHR by Yuqi Zhang, Sijin Li, Peibiao Mai, Yanqi Yang, Niansang Luo, Chao Tong, Kuan Zeng, Kun Zhang

Subjects: “…Atrial fibrillation…”
Get full text

AI prediction model for endovascular treatment of vertebrobasilar occlusion with atrial fibrillation by Zhi-Xin Huang, Andrea M. Alexandre, Alessandro Pedicelli, Xuying He, Quanlong Hong, Yongkun Li, Ping Chen, Qiankun Cai, Aldobrando Broccolini, Luca Scarcia, Serena Abruzzese, Carlo Cirelli, Mauro Bergui, Andrea Romi, Erwah Kalsoum, Giulia Frauenfelder, Grzegorz Meder, Simona Scalise, Maria Porzia Ganimede, Luigi Bellini, Bruno Del Sette, Francesco Arba, Susanna Sammali, Andrea Salcuni, Sergio Lucio Vinci, Giacomo Cester, Luisa Roveri, Xianjun Huang, Wen Sun

“…Abstract Endovascular treatment (EVT) for vertebrobasilar artery occlusion (VBAO) with atrial fibrillation presents complex clinical challenges. …”
Get full text

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria by Yazid Aoudia, Thitima Kongnakorn, Evie Merinopoulou, Mohamed Said Bettayeb, Sid Ahmed Kherraf

“…**Background:** Atrial fibrillation (AF) is a chronic sustained heart rhythm disorder associated with an increased risk of stroke. …”
Get full text

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF) by Raffaele De Caterina, Kurt Huber, Richard Schilling, Miklos Rohla, Thomas W Weiss, Ladislav Pecen, Giuseppe Patti, Jolanta M Siller-Matula, Renate B Schnabel, Dipak Kotecha, Markus Lucerna, Paulus Kirchhof

“…Objectives We identified factors associated with thromboembolic and bleeding events in two contemporary cohorts of anticoagulated patients with atrial fibrillation (AF), treated with either vitamin K antagonists (VKA) or non-VKA oral anticoagulants (NOACs).Design Prospective, multicentre observational study.Setting 461 centres in seven European countries.Participants 5310 patients receiving a VKA (PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF), derivation cohort) and 3156 patients receiving a NOAC (PREFER in AF Prolongation, validation cohort) for stroke prevention in AF.Outcome measures Risk factors for thromboembolic events (ischaemic stroke, systemic embolism) and major bleeding (gastrointestinal bleeding, intracerebral haemorrhage and other life-threatening bleeding).Results The mean age of patients enrolled in the PREFER in AF registry was 72±10 years, 40% were female and the mean CHA2DS2-VASc Score was 3.5±1.7. …”
Get full text

The Effects of Catheter Ablation Therapy on Medication Use and Expenditures in Patients with Atrial Fibrillation by Matthew R. Reynolds, Guy David, Candace Gunnarsson, Jamie L. March, Steven C. Hao

“…**Background:** Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. …”
Get full text

Narrative Literature Review of Potential Atrial Fibrillation Mechanism of Action Induced by Discontinuation of Benzodiazepines by Agnė Okulevičiūtė, Gabija Laubner Sakalauskienė

Subjects: Get full text

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation by Li Wang, Elyse Fritschel, Onur Baser

“…**Background:** Atrial fibrillation (AF) is a common clinical problem and potent risk factor for stroke. …”
Get full text

Functional feature extraction and validation from twelve-lead electrocardiograms to identify atrial fibrillation by Wei Yang, Rajat Deo, Wensheng Guo

“…Abstract Background Deep learning methods on standard, 12-lead electrocardiograms (ECG) have resulted in the ability to identify individuals at high-risk for the development of atrial fibrillation. However, the process remains a “black box” and does not help clinicians in understanding the electrocardiographic changes at an individual level. we propose a nonparametric feature extraction approach to identify features that are associated with the development of atrial fibrillation (AF). …”
Get full text

Machine Learning in the Management of Patients Undergoing Catheter Ablation for Atrial Fibrillation: Scoping Review by Aijing Luo, Wei Chen, Hongtao Zhu, Wenzhao Xie, Xi Chen, Zhenjiang Liu, Zirui Xin

“… BackgroundAlthough catheter ablation (CA) is currently the most effective clinical treatment for atrial fibrillation, its variable therapeutic effects among different patients present numerous problems. …”
Get full text

Comparative safety and effectiveness of cryoballoon versus radiofrequency ablation for atrial fibrillation: a systematic review and meta-analysis by Muhammad Furqan, Ifrah Inbisat Raza, Shaheera Younus, Hareer Fatima, Hiba Azhar, Sania Kaneez Fatima, Laiba Ali, Sara Khan, Aayat Ellahi

Subjects: “…Atrial fibrillation…”
Get full text

Validation of MyDiagnostick tool to identify atrial fibrillation in a multi-ethnic Asian population by Colin Yeo, Aye Aye Mon, Vern Hsen Tan, Kelvin Wong

“…Introduction: MyDiagnostick is an atrial fibrillation (AF) screening tool that has been validated in the Caucasian population in the primary care setting. …”
Get full text

Prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia: a narrative review by Tatyana S. Degtyareva, Kristina G. Pereverzeva, Sergey S. Yakushin, Natalia N. Peregudova

Subjects: Get full text

MicroRNAs in atrial fibrillation – have we discovered the Holy Grail or opened a Pandora’s box? by Alkora Ioana Balan, Alina Scridon

Subjects: Get full text

Cryoballoon ablation for atrial fibrillation in South Africa: One-year outcome from the Cryo Global Registry by A Stanley, K A van Bragt, V Obidigbo, B Vezi

Subjects: “…atrial fibrillation…”
Get full text

Early Outcomes With Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation by Shashank Shekhar, MD, Amar Krishnaswamy, MD, Grant Reed, MD, MSc, James Yun, MD, Rishi Puri, MD, PhD, Samir Kapadia, MD

“…We aimed to analyze the impact of CPD use during TAVR among patients with atrial fibrillation (AF). Methods: Data on adult TAVR patients with a concomitant diagnosis of AF was obtained from the 2017-2020 National Readmissions Database. …”
Get full text

Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective by Yaariv Khaykin, Peter J. Mallow, John A. Rizzo, Atul Verma, Lauren Chun, Shelby Olesovsky, Matthew R. Reynolds

“…**Background:** Atrial fibrillation (AF) affects approximately 350,000 Canadians and has an estimated annual economic burden exceeding $800 million dollars. …”
Get full text

Japanese Patients’ and Physicians’ Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment by Ken Okumura, Hiroshi Inoue, Masahiro Yasaka, Juan Marcos Gonzalez, A. Brett Hauber, Bennett Levitan, Zhong Yuan, Jean Baptiste Briere

“…**Background:** Anticoagulants are recommended for stroke prevention in patients with atrial fibrillation (AF), but are associated with an increased risk of bleeding; therefore, physicians face benefit-risk tradeoffs when prescribing anticoagulants to AF patients. …”
Get full text

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain by Carlos Rubio-Terrés, Ruth Graefenhain de Codes, Darío Rubio-Rodríguez, Thomas Evers, Santiago Grau Cerrato

“…**Objective:** The aim of this study was to evaluate, from the Spanish National Health System perspective, the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol (5 mg/day) for the treatment of patients with non-valvular atrial fibrillation (NVAF) at moderate to high risk for stroke. …”
Get full text